ERBB2 D769Y

CI-VAR-00000535Explore in graph →NP_004439.2:p.Asp769TyrNM_004448.3:c.2305G>TClinVar 375992 CIViC 36 rs121913468

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 3 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Extramammary Paget Disease1
ERBB2 D769Y	Afatinib	Predictive	C	Supports Sensitivity Response	3	accepted	EID11688 In this phase II NCI-MATCH trial, a patient with extra-mammary Paget disease of the skin with ERBB2 D769Y mutation was treated with afatinib. A confirmed RECIST response was reported in the patient wh… (full text at CIViC) PMID 35939768 · Bedard et al., 2022 · Open in CIViC	civic
Malignant Breast Neoplasm1
ERBB2 D769Y	Neratinib	Predictive	D	Supports Sensitivity Response	4	accepted	EID280 In MCF10A cell lines, the D769Y mutation was shown to be sensitive to neratinib. PMID 23220880 · Bose et al., 2013 · Open in CIViC

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Peritoneal Carcinoma1unmapped disease
ERBB2 D769Y	Afatinib	Predictive	C	Supports Sensitivity Response	1	accepted	EID11689 In this phase II NCI-MATCH trial, a patient with primary peritoneal carcinoma with ERBB2 D769Y mutation was treated with afatinib. A RECIST response was reported in the patient, however, it wasn't con… (full text at CIViC) PMID 35939768 · Bedard et al., 2022 · Open in CIViC	civic